Johnson & Johnson Details Head and Neck Tumour Responses in OrigAMI-4

Johnson & Johnson announced company-reported results from Cohort 5 of the Phase 1b/2 OrigAMI-4 study of an investigational first-line regimen in recurrent or metastatic head and neck squamous cell carcinoma. The regimen combines subcutaneous amivantamab and hyaluronidase-lpuj, a PD-1 inhibitor and fixed-duration carboplatin chemotherapy. Johnson & Johnson says the findings support the ongoing pivotal Phase 3 OrigAMI-5 study. The regimen remains investigational in this setting. Johnson & Johnson News report.

What Johnson & Johnson Reported

Johnson & Johnson released results from Cohort 5 of the Phase 1b/2 OrigAMI-4 study, which evaluated subcutaneous amivantamab and hyaluronidase-lpuj with a PD-1 inhibitor and fixed-duration carboplatin chemotherapy in previously untreated recurrent or metastatic head and neck squamous cell carcinoma. The company described the responses as deep and durable, and said the findings support the ongoing pivotal Phase 3 OrigAMI-5 study.

The company reported response findings for patients whose cancer was not HPV-associated oropharyngeal squamous cell carcinoma, presenting the data at a medical congress. These are company-reported early-phase findings rather than independent confirmation. Investigators assessed response as the study primary endpoint.

Related coverage: Biopharma research.

Response Is Not Survival

Our analysis distinguishes the reported tumour responses from a demonstrated survival benefit. Johnson & Johnson also stated that median overall survival was not reached in the cohort. The company describes the findings as supporting continued evaluation of the investigational regimen.

Our analysis does not interpret response activity in this early-phase cohort as proof of superiority over another treatment. We would look to the ongoing pivotal Phase 3 OrigAMI-5 study for further evidence rather than infer a comparative treatment conclusion from this release. These are separate stages of clinical development, not interchangeable findings.

Related coverage: Clinical development.

How the Investigational Regimen Is Designed

Subcutaneous amivantamab is described by the company as a bispecific antibody designed to target EGFR and MET while engaging the immune system. The company states that overexpression of these pathways is seen in most head and neck squamous cell carcinoma tumors and has been implicated in tumor progression and treatment resistance.

The cohort combined this agent with a PD-1 inhibitor and a fixed-duration course of carboplatin. Johnson & Johnson noted that its experience with the subcutaneous formulation in EGFR-mutated lung cancer helped establish the potential of dual targeting. The company characterized the head and neck regimen as investigational in this setting.

Related coverage: Treatment research.

Safety Findings as Stated

Johnson & Johnson said the safety profile of the combination was consistent with the individual agents. The company listed anemia, hypoalbuminemia, thrombocytopenia and stomatitis among the most common adverse events, and reported administration-related reactions associated with subcutaneous amivantamab, with no Grade 3 or higher events reported for those reactions.

These are company-reported observations from a single early-phase cohort, not a determination that the regimen is safe. The source does not establish an acceptable safety profile, and the company cautions that clinical success and regulatory approval remain uncertain. Separate approved labeling for the subcutaneous product addresses lung cancer, not this head and neck combination.

Related coverage: Drug development.

What This Means for Practitioners

Our editorial recommendation is to read the cohort findings alongside the ongoing Phase 3 programme, rather than interpret response activity as confirmed comparative benefit. Readers should keep the treatment setting and development stage attached to any summary of the results. A company release describes research; it does not replace approved prescribing information or individual medical advice. The next evidence to examine is the Phase 3 study, including its efficacy and safety findings, rather than extrapolating from this early-phase cohort.